Men with prostate cancer that has spread to other parts of the body and that is resistant to hormone therapy suffer less from fatigue if they are treated with a combination of abiraterone acetate and prednisone, according to a new study. Significant improvements in fatigue are important for this group of difficult-to-treat patients who had few available therapeutic options, and for whom fatigue is one of the most distressing issues they face.